Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
NEW YORK, Jan. 27, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased TG Therapeutics, Inc. (NASDAQ:TGTX) securities between September 15, 2014 and October 12, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/tg-therapeutics-inc. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, TGTX misrepresented and/or omitted material information concerning its GENUINE Phase III clinical trial for its proprietary combination of drug therapies TG-1101 and TGR-1202. The Phase III trial consisted of two parts, Part I evaluating the effect of the addition of TG-1101 to ibrutinib on overall response rate (ORR) in approximately 200 patients, and Part II evaluating the effect of the addition of TG-1101 to ibrutinib on progression-free survival (PFS) in all study patients. During the class period TGTX repeatedly assured investors as to the efficacy and potential FDA approval of the treatment, referring to it as a “best-in-class treatment.” Then on October 13, 2016, TGTX announced that it would abandon Part II of the study, thus annulling its filed Special Protocol Assessment with the FDA and cutting enrollment and increasing the likelihood that the FDA would not approve the combination treatment.
If you suffered a loss in TG Therapeutics you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/tg-therapeutics-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
